Introduction
============

In 1998, Hsu *et al* ([@b1-mco-0-0-934]) found that the leucine-rich repeat-containing G-protein coupled receptor 5 (Lgr5) was homologous to the gonadotropin and thyrotropin receptors in Drosophila ([@b1-mco-0-0-934]). Lgr5 is expressed in the eye, brain, mammary glands, hair follicles, stomach, intestines and other tissues ([@b2-mco-0-0-934],[@b3-mco-0-0-934]). Lgr5 serves an important role in the Wnt signaling pathway, which is intimately involved in tumor development ([@b4-mco-0-0-934]--[@b6-mco-0-0-934]). Lgr5 is a marker of stem cells in the intestine, mammary glands and hair follicles. Lgr5 is also expressed in intestinal tumors ([@b7-mco-0-0-934],[@b8-mco-0-0-934]), which are composed of crypt base columnar cells and stem cells. In addition, Lgr5 is expressed in hepatocellular carcinoma, breast cancer and gastric carcinoma. However, its role in normal lung and in lung cancer remains unknown.

Lung cancer is the leading cause of cancer-assocaited mortality among males in developed countries ([@b9-mco-0-0-934]). Few studies reporting on Lgr5 in lung cancer have been published in recent years ([@b10-mco-0-0-934],[@b11-mco-0-0-934]). To investigate whether Lgr5 serves a role in lung cancer similar to that in colorectal cancer and to determine whether Lgr5 functions in the maintenance of lung structure, the present study assessed the structure of the lungs in Lgr5 heterozygous knockout mice (Lgr5^+/−^). Notbaly, it was demonstrated that the lungs of Lgr5^+/−^ mice were abnormal compared with those of wild-type (WT) mice, which suggested that Lgr5 functions in the maintenance of normal lung structure. Furthermore, Lgr5 expression was analyzed in tumor tissues of patients with lung cancer. The present study indicated that Lgr5 serves an important role in lung adenocarcinoma and provided some meaningful insight into the presence of Lgr5-positive cells in the lungs and Lgr5 expression in lung cancer.

Materials and methods
=====================

### Mice

Genetically engineered mice \[B6.129P2-Lgr5tm1 (cre/ERT2) Cle/J\] were donated to our laboratory by Professor Geng (Department of Biologic and Materials Sciences, University of Michigan School of Dentistry, Ann Arbor, MI, USA). This mouse model was produced by knock-in of the Lgr5-EGFP-IRES-creERT2 allele, which results in the loss of function of one Lgr5 allele and the expression of the CreERT2-EGFP fusion protein. Lgr5 mice do not exhibit any obvious abnormalities in terms of birth rate or any abnormal physiological properties. By contrast, the homozygous deletion of Lrg5 in mice resulted in neonatal lethality ([@b12-mco-0-0-934]). To investigate the role of Lgr5 in the lungs, Lgr5^+/−^ mice were used in the present study. The mice were housed in an individual ventilated cage (IVC) environment at 24±2°C and 60±5% humidity with 12 h light/dark cycles. The mice were fed a bacteria-free diet. All mice were sacrificed under diethyl ether anesthesia. Guangdong College of Pharmacy Approved Animal Ethics Committee approved all murine experiments. To identify the genotype of the mice, DNA was extracted from a 0.5--1 cm portion of the tail. The DNA was amplified in polymerase chain reaction (PCR) amplification buffer (2X PCR mix; Promega, Beijing, China), and the PCR products were subsequently run on a 2% agarose gel. The PCR product of the homozygous mice was 174 bp, the heterozygous mice PCR product was 174 bp and the WT mice product was 298 bp. The primers used were as follows: Common (sequence no. 8060), 5′-CTGCTCTCTGCTCCCAGTCT-3′; WT reverse (sequence no. 8061), 5′-ATACCCCATCCCTTTTGAGC-3′; mutant reverse (oIMR9402) 5′-GAACTTCAGGGTCAGCTTGC-3′. The PCR system and PCR reaction conditions were in accordance with the protocols of the Jackson Laboratory (Bar Harbor, ME, USA).

### Collection of tissue specimens

Lgr5 expression was evaluated in a total of 42 primary non-small cell lung cancers (NSCLCs) and 28 matched normal adjacent lung tissue samples by immunohistochemistry (IHC). The 42 samples included 22 lung adenocarcinoma samples and 20 squamous cell carcinoma samples. In addition, a tissue microarray (TMA) that contained 80 cases of lung adenocarcinoma was also included. Therefore, the total number of lung adenocarcinoma cases was 102, whereas the total number of squamous cell carcinoma samples was 20. The clinical features of the patients with NSCLC are outlined in [Table I](#tI-mco-0-0-934){ref-type="table"}. All specimens were collected from patients who were admitted to the Department of Thoracic Surgery, Sun Yat-Sen University Cancer Center, (Guangzhou, China) between October 9, 2009 and July 12, 2014 with patient consent and institutional review board approval. All patients signed informed consent for the use of their clinical specimens for medical research. The samples in this study were approved by the Committee for Ethical Review of Research at Sun Yat-Sen University.

### Histology

The paraffin embedded tissues were sectioned at a thickness of 3--5 µm, and hematoxylin and eosin (H&E) staining was performed, as previously described ([@b13-mco-0-0-934]). Briefly, IHC was performed as follows: Antigen retrieval with ethylenediaminetetraacetic acid solution (pH 9.0), incubation of the slides in 3% H~2~O~2~ at room temperature for 12 min, followed by washes and the blocking of non-specific proteins. The antibody was applied to the slides, which were subsequently incubated at 4°C overnight. The tissue sections were washed again and the secondary antibody was applied to the slides. Finally, diaminobenzidine was used to visualize the positive staining on the slides. The primary Lgr5 antibody was used at a dilution of 1:100 (cat. no. sc-135238; Santa Cruz Biotechnology, Inc., Santa Cruz, CA, USA). The anti-rabbit secondary antibody was conjugated to horseradish peroxidase and was used at a dilution of 1:500 (cat. no. GK500705). The diaminobenzidine chromogen system was purchased from Gene Tech Co., Ltd. (Shanghai, China). The slides were viewed on a BX51 Olympus microscope (Olympus Corporation, Shibuya, Japan).

### Statistical analysis

All statistical analyses were performed using GraphPad Prism software version 5 (Graphpad Software, CA, USA). The χ^2^ test or Fisher\'s exact test was used to analyze the association of Lgr5 expression with the clinicopathological parameters of the patients. The survival curves were plotted according to the Kaplan-Meier method to evaluate the Lgr5 expression levels with respect to the survival rate. The multivariate survival analyses were performed by a Cox proportional hazard model using the Wald test. P\<0.05 was considered to indicate a statistically significant difference..

Results
=======

### Lgr5-positive cells are present in mouse lung tissue

Lgr5 is well-characterized as a marker of normal stem cells in the intestine and as a marker of cancer stem cells. The Lgr5 homozygous knockout in mice resulted in neonatal lethality ([@b12-mco-0-0-934]). The present study suggested that Lgr5 serves an important role in development. However, the role of Lgr5-positive cells in the lung remains unknown. To investigate whether cells in normal mouse lung express Lgr5, normal lung tissue was obtained from C57/BL WT mice and the expression of Lgr5 was determined by IHC using a specific antibody. To confirm that the antibody was specific, normal mouse intestine was stained. The results are shown in [Fig. 1A](#f1-mco-0-0-934){ref-type="fig"}. In the lung tissue, the results demonstrated that some Lgr5-positive cells were present in the bronchi and alveoli ([Fig. 1B and C](#f1-mco-0-0-934){ref-type="fig"}). The present study next determined whether the knockout of Lgr5 affected lung structure and found that the structure of the lung tissue of Lgr5 heterozygous knockout mice (Lgr5^+/−^ mice) differed from that of the WT mice. This finding indicated that the lung septa of Lgr5^+/−^ mice were thicker and that the lung structure was irregular compared with the WT mice ([Fig. 1E](#f1-mco-0-0-934){ref-type="fig"}).

### Lgr5 is expressed in lung adenocarcinoma, but not in squamous carcinoma

Based on the above IHC and histology results, the present study hypothesized that Lgr5 may serve a function in the maintenance of the morphology of bronchi or alveoli in the normal lung. It must be considered that lung tumor initiating cells are partly derived from the bronchi and that Lgr5 is a well-known marker of intestinal cancer stem cells. Therefore, in lung cancer, the present study assumed that Lgr5 is associated with tumor formation or to the tumor, node, metastasis (TNM) stage. Next, 122 lung cancer cases, including 102 cases of adenocarcinoma and 20 cases of squamous carcinoma, were subjected to IHC. The results showed that Lgr5 is not expressed in squamous cell carcinoma (0/20; P\<0.001; [Table I](#tI-mco-0-0-934){ref-type="table"}; [Fig. 2A](#f2-mco-0-0-934){ref-type="fig"}), however, is expressed in adenocarcinoma (47/122). The representative image of the staining is presented in [Fig. 2B and C](#f2-mco-0-0-934){ref-type="fig"}. Notably, in certain cases, Lgr5-positive cells were present in areas of tumor necrosis ([Fig. 2D](#f2-mco-0-0-934){ref-type="fig"}), areas adjacent to the tumor ([Fig. 2E](#f2-mco-0-0-934){ref-type="fig"}), and the lymphatic spaces and vascular lumina ([Fig. 2F](#f2-mco-0-0-934){ref-type="fig"}).

### Survival analysis of patients with lung adenocarcinoma as a function of Lgr5 expression

The above data showed that Lgr5 is expressed in lung adenocarcinoma, but not in squamous carcinoma. Furthermore, the present study stained one tissue microarray that included 60 cases of lung adenocarcinoma to assess its expression by IHC using an Lgr5 antibody. These cases were classified into two groups as either '+' or '-', as shown in the representative image in [Fig. 3A](#f3-mco-0-0-934){ref-type="fig"}. The positive group was indicated by '+' and the negative group was indicated by '-'.

A survival analysis was performed for all patients with lung adenocarcinoma (paraffin blocks, 22 cases; TMA, 80 cases) using the Kaplan-Meier method. The follow-up periods ranged between 4 and 157 months. To evaluate the association between Lgr5 expression in lung adenocarcinoma cells and the clinicopathological parameters, the data from the patients was summarized in [Table I](#tI-mco-0-0-934){ref-type="table"}. Lgr5 expression was not associated with tumor size (P=0.075). In addition, no significant association was observed between Lgr5 expression and age, gender, tumor invasion or lymph node metastasis. However, Lgr5 expression was associated with TNM stage (P=0.026).

Additionally, the median survival was 30.5 months for patients in the Lgr5-negative group (n=55) and 12 months (n=47) for patients in the Lgr5-positive group, which indicated a significantly poorer survival rate of the Lgr5-positive group compared with the Lgr5-negative group (P=0.033). Next, univariable and multivariable analyses were performed to assess the effect of Lgr5 expression on survival. A Cox proportional hazards regression model was subsequently applied and the effect of Lgr5 on survival was estimated. The crude hazard ratio (HR) of the Lgr5-positive tumors compared with the Lgr5-negative tumors was 1.618 \[95% confidence interval (CI), 1.06--2.48; P=0.027\]. To estimate the independent pro-diagnostic effect of Lgr5 on survival, the present study adjusted for confounding factors. The present study involved 59 lung adenocarcinoma patients with lung cancer-associated mortalities and 5 variables that were included in the multivariate regression model. To determine whether Lgr5 expression was a single variable and not a potential confounding factor, a propensity score was applied. The five variables were clinicopathological factors, including age, tumor size, TNM stage, tumor invasion and metastasis. The adjusted HR of the Lgr5-positive group was 0.396 (95% CI, −0.28--1.06; P=0.15) compared with the Lgr5-negative group, which suggested that Lgr5 expression is not an independent risk factor for poorer survival ([Table II](#tII-mco-0-0-934){ref-type="table"}).

Discussion
==========

Lgr5 is regarded as a marker of intestinal stem cells, which has attracted a significant amount of attention to this protein ([@b8-mco-0-0-934],[@b14-mco-0-0-934]--[@b19-mco-0-0-934]). However, its role in the lungs and in lung cancer remains unclear ([@b10-mco-0-0-934]). The present study demonstrated for the first time, to the best of our knowledge, that the lungs of Lgr5 heterozygous mice exhibited structural abnormalities. Specifically, the pulmonary interstitium was thickened according to H&E staining. Additionally, Lgr5-positive cells were found in the mouse lung, including the alveoli. In addition, a few cells expressing Lgr5 were also found in the basal layer of the bronchial tissue. The above results suggested that Lgr5 may serve a significant role in the lung bronchi and alveoli. However, a determination of the function of these positive cells requires further clarification.

In both the human and mouse gut, Lgr5-positive cells located in the intestinal crypts protect Paneth cells and are regarded as tumor stem cells ([@b18-mco-0-0-934]). In the present study, it was revealed that certain cells in normal lung tissue express Lgr5. This finding led us to question whether Lgr5 serves a role in normal lung tissue or if it is associated with lung cancer. Certain lung cancer cells are derived from the lung bronchi; therefore, Lgr5 expression in lung tumor tissues from patients with lung cancer was examined. Notably, Lgr5 is only expressed in lung adenocarcinoma and its expression is associated with TNM stage; however, Lgr5 expression not an independent factor for survival. In another study, the Lgr5-positive rate in lung adenocarcinoma was \~1/10 ([@b11-mco-0-0-934]). However, in the present study, the rate reached \~50%. However, as the reasons that underlie this difference are unknown, additional studies are required for clarification.

In previous studies, researchers have demonstrated that Lgr5 expression is associated with colorectal tumorigenesis and even colorectal cancer recurrence ([@b20-mco-0-0-934]). Previous studies have also reported that Lgr5 expression is correlated with tumor invasion and metastasis ([@b15-mco-0-0-934],[@b21-mco-0-0-934],[@b22-mco-0-0-934]). However, in the present experiments, the data did not indicate this phenomenon in lung adenocarcinoma. This difference may be because Lgr5 serves different roles in lung tumors compared with intestinal tumors. Notably, the presence of Lgr5-positive cells in lymphatic vessels were observed. Therefore, more experiments are required to investigate whether Lgr5 expression is associated with tumor metastasis ([Fig. 3C](#f3-mco-0-0-934){ref-type="fig"}).

In conclusion, the present study provided novel insights into the role of Lgr5 in normal lung tissue and lung cancer. It will be conducive for us to learn the role and function of Lgr5 in lung cancer.
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![Lgr5 expression in the mouse lung. (A) The sensitivity of the Lgr5 antibody was confirmed by staining intestinal tissue of WT mice. Lgr5-positive cells are indicated by arrows. (B) A few Lgr5-positive cells are present in the alveoli of mouse lung, as indicated by arrows (magnification, ×1,000). (C) A few Lgr5-positive cells were present in the lung bronchi (magnification, ×1,000), as indicated by arrows. (D) Identification of Lgr5^+/−^ mice was performed by genotyping. Bands of 298 bp and 174 bp were obtained by polymerase chain reaction amplification and are indicative of the Lgr5^+/−^ genotype. Lanes 1 and 3--5 are WT mice and lane 2 is the Lgr5^+/−^ mouse. (E) Representative hematoxylin and eosin staining of Lgr5^+/−^ mouse lung and WT mouse lung tissue. Interlobular septa of Lgr5^+/−^ mouse lung are thickened and abnormal hyperplasia in the bronchi and light pulmonary congestion were also observed (magnification, ×200). WT, wild-type; Lgr5, Leucine-rich repeat-containing G-protein coupled receptor 5; bp, base pairs; M, marker.](mco-05-02-0283-g00){#f1-mco-0-0-934}

![Lgr5 is expressed in lung adenocarcinoma and is not expressed in squamous carcinoma. (A) A representative image of Lgr5 negativity in squamous carcinoma (magnification, ×400). (B) A representative image of lung adenocarcinoma indicates that certain samples did not express Lgr5 (magnification, ×400). (C) Certain lung adenocarcinoma tissues expressed Lgr5 (magnification, ×400). (D) Lgr5-positive cells are present in the necrotic area of the tumor tissues (magnification, ×1,000). (E) Lgr5-positive cells also appear in regions adjacent to the carcinoma (magnification, ×400). (F) Lgr5-positive cells in the lumen (magnification, ×1,000). Lgr5, Leucine-rich repeat-containing G-protein coupled receptor 5.](mco-05-02-0283-g01){#f2-mco-0-0-934}

![Survival analysis. (A) A representative image of the TMA immunohistochemistry results demonstrating negative (left) and positive (right) Lgr5 staining. (B) Kaplan-Meier analysis revealed that Lgr5 expression was significantly associated with poor overall survival of patients with lung adenocarcinoma (P=0.019). Lgr5, Leucine-rich repeat-containing G-protein coupled receptor 5; TMA, tissue microarray.](mco-05-02-0283-g02){#f3-mco-0-0-934}

###### 

Correlation between Lgr5 expression and the clinical and pathological characteristics of 122 cases of primary non-small cell lung cancer.

                                                                                                              Lgr5 expression (%)                 
  ----------------------------------------------------------------------------------------------------- ----- --------------------- ------------- ---------
  Gender                                                                                                                                          0.269
    Male                                                                                                75    49 (65.3)             26 (34.7)     
    Female                                                                                              47    26 (55.3)             21 (44.7)     
  Age                                                                                                                                             0.421
    ≤60-years-old                                                                                       68    46 (67.6)               22 (32.4)   
    \>60-years-old                                                                                      64    39 (60.9)             25 (39.1)     
  Tumor size^[a](#tfn1-mco-0-0-934){ref-type="table-fn"},[b](#tfn2-mco-0-0-934){ref-type="table-fn"}^                                             0.075
    ≤5 cm^3^                                                                                            59    31 (52.5)             27 (47.5)     
    \>5 cm^3^                                                                                           63    43 (84.10)            20 (15.9)     
  Tumor invasion^[c](#tfn3-mco-0-0-934){ref-type="table-fn"}^                                                                                     0.351
    T1                                                                                                  12    6 (50.0)              6 (50.0)      
    T2                                                                                                  65    28 (43.1)             37 (56.9)     
    T3                                                                                                  45    27 (60.0)             18 (40.0)     
  Lymph node metastasis                                                                                                                           0.569
    N0                                                                                                  82    52 (63.4)             30 (36.6)     
    N1                                                                                                  40    23 (57.5)             17 (42.5)     
  AD and SS                                                                                                                                       \<0.001
    Adenocarcinoma                                                                                      102   55 (53.9)             47 (46.1)     
    Squamous                                                                                            20    20 (100)              0 (0.0)       
  TNM stage^[d](#tfn4-mco-0-0-934){ref-type="table-fn"}^                                                                                          0.026
    I--II                                                                                               81    56 (69.1)             25 (30.9)     
    III--IV                                                                                             41    19 (46.3)             22 (53.7)     

Tumor size was measured and obtained by the formula 0.5 × length × (width)^2^.

Partial data are not available and all statistics were based on the informative data.

Invasion was defined by results of the final pathological analysis.

Each case was reassigned a pathological stage according to the 7^th^ edition of the TNM classification. AD, adenocarcinoma; SS, squamous carcinoma; TNM, tumor node metastasis; Lgr5, Leucine-rich repeat-containing G-protein coupled receptor 5.

###### 

Univariate and multivariate analyses of the overall survival rate and the clinicopathological parameters of 122 patients with lung cancer using the Cox proportional hazards regression model.

                          Univariate^[a](#tfn5-mco-0-0-934){ref-type="table-fn"}^   Multivariate^[b](#tfn6-mco-0-0-934){ref-type="table-fn"}^   
  ----------------------- --------------------------------------------------------- ----------------------------------------------------------- ---------
  Age                     0.136                                                     1.32 (0.944--2.435)                                         0.094
    ≤60-years-old                                                                                                                               
    \>60-years-old                                                                                                                              
  Tumor size              0.032                                                     1.12 (0.832--1.482)                                         0.696
    ≤10 cm^3^                                                                                                                                   
    \>10 cm^3^                                                                                                                                  
  Tumor invasion          0.033                                                     1.58 (0.951--2.810)                                           0.173
    T1                                                                                                                                          
    T2                                                                                                                                          
    T3                                                                                                                                          
  Lymph node metastasis   0.001                                                       1.812 (0.611--4.650)                                      0.308
    N0                                                                                                                                          
    N1                                                                                                                                          
  TNM stage               0.005                                                       0.861 (0.470--2.667)                                      0.897
    I--II                                                                                                                                       
    III--IV                                                                                                                                     
  Lgr5                    0.076                                                     3.36 (1.24--10.63)                                          0.036
    Negative                                                                                                                                    
    Positive                                                                                                                                    

Kaplan-Meier

Cox proportional hazards regression model. TNM, tumor node metastasis; Lgr5, Leucine-rich repeat-containing G-protein coupled receptor 5.
